Durabolin25 mg/ml

Durabolin 25 mg/ml is indicated- As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance For the palliative treatment of selected cases of disseminated mammary carcinoma in women Osteoporosis.

Anabolic steroid (Androgens), Hormone in bone formation by stimulation

Durabolin 25 mg/ml is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The phenylpropionate ester gives the preparation a duration of action of about one week after injection. Nandrolone is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor binding studies. The low androgenicity of nandrolone is confirmed in clinical use.In the human, Durabolin 25 mg/ml has a nitrogen saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists such as during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Durabolin 25 mg/ml serves as a supportive adjunct to specific therapies and dietary measures. In women with disseminated mammary carcinoma, in selected cases Durabolin 25 mg/ml has been reported to produce objective regressions for many months. Furthermore, Durabolin 25 mg/ml has been shown to produce relief of bone pain in patients with osteoporosis. The similarly acting nandrolone ester, nandrolone decanoate, has been shown to increase bone mineral content in these patients. Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: Recommended dose is 25-50 mg every week.For the palliative treatment of selected cases of disseminated mammary carcinoma in women: Recommended dose is 50 mg every week.Osteoporosis: Recommended dose is 50 mg every week.For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet. Durabolin 25 mg/ml should be administered by deep intramuscular injection.

As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: Recommended dose is 25-50 mg every week.For the palliative treatment of selected cases of disseminated mammary carcinoma in women: Recommended dose is 50 mg every week.Osteoporosis: Recommended dose is 50 mg every week.For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet. Durabolin 25 mg/ml should be administered by deep intramuscular injection.

Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other antidiabetic medicines in diabetics.

Contraindicated in Pregnancy, Known or suspected carcinoma of the prostate or breast in the male.

High dosages, prolonged treatment and/or too frequent administration may cause: Virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice. Amenorrhoea. Inhibition of spermatogenesis. Premature epiphyseal closure. Fluid retention.

This medicine is contraindicated during pregnancy because of possible masculinization of the foetus. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the infant or a possible influence on milk production.

If signs of virilisation develop, discontinuation of the treatment should be considered, Preferably in consultation with the patient.It is recommended to monitor patients with any of the following conditions: latent or overt cardiac failure, renal dysfunction, hypertension or migraine (or a history of these conditions), since anabolic steroids may occasioally induce fluid retention: incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases of breast carcinoma. In these patients hypercalcaemia may develop both spontaneously and as a result of anabolic steroid therapy. The later can be indicative of a positive tumour response to the hormonal treatment. Nevertheless, the hypercalcaemia should first be treated appropriately and after restoration of normal calcium levels hormone therapy can be resumed; liver dysfunction. The use of anabolic steroids to enhance athletic ability may carry severe risks to the user's health and should be discouraged.

The acute toxicity of Durabolin 25 mg/ml in animals is very low. There are no reports of acute overdosage with Durabolin 25 mg/ml in the human

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Anabolic steroid (Androgens), Hormone in bone formation by stimulation

Durabolin 25 mg/ml is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The phenylpropionate ester gives the preparation a duration of action of about one week after injection. Nandrolone is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor binding studies. The low androgenicity of nandrolone is confirmed in clinical use.In the human, Durabolin 25 mg/ml has a nitrogen saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists such as during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Durabolin 25 mg/ml serves as a supportive adjunct to specific therapies and dietary measures. In women with disseminated mammary carcinoma, in selected cases Durabolin 25 mg/ml has been reported to produce objective regressions for many months. Furthermore, Durabolin 25 mg/ml has been shown to produce relief of bone pain in patients with osteoporosis. The similarly acting nandrolone ester, nandrolone decanoate, has been shown to increase bone mineral content in these patients. Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

This medicine is contraindicated during pregnancy because of possible masculinization of the foetus. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the infant or a possible influence on milk production.